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Abstract: 
Fluorenylethylchoroformate (FLEC) is a valuable chiral derivatisation reagent that is used 
for the resolution of a wide variety of chiral amines. Herein we describe an improved 
preparation of (S)-(-)-FLEC using an efficient asymmetric catalytic transfer hydrogenation 
as the key step. We also demonstrate the application of FLEC as a chiral Fmoc equivalent 
for chiral resolution, with facile deprotection, of tetrahydroquinaldines, and its capacity for 
inducing regioselective outcomes in nitration reactions. 
 
Introduction: 
Fluorenylethylchloroformate (FLEC) is a useful and versatile reagent for the 
diastereomeric resolution of amino acids and amines.1,2 Since its introduction, 
FLEC has been applied to the analysis of many natural and synthetic products and 
these have been the subject of a comprehensive recent review.3 It is however very 
expensive to purchase which has limited its application in synthesis.  
 
2 
 
We have previously described  an improved route to (R)-(+)-FLEC, (R)-4 from 
flourene (1), via ketone 2 and alcohol 3 (Scheme 1) using the Corey-Bakshi-Shibata 
(CBS) reaction and its application to the synthesis of unusual chiral amino acids in 
peptide research.4 Fluorenylethyloxycarbonyl (Feoc) derivatives could act both as 
an amino acid resolving agent and protecting group for peptide synthesis. 
Borowiecki and co workers recently reported an alternate method to prepare the 
alcohol (S)-3 based on enzymatic kinetic resolution.5 In their method, 9-
acetylfluorene (2) was prepared by refluxing 9H-fluorene (1) with EtOAc in ether 
and under strongly basic conditions (a mixture of t-BuOK and t-BuONa) for 3 h in 
a high isolated yield (97%). This ketone was then reduced to the racemic alcohol by 
sodium borohydride (NaBH4). Lipase-catalysed kinetic resolution yielded the the 
enantiopure S-alcohol and the R-acetate.  
 
Results and Discussion. 
The success of the asymmetric CBS reduction was still short of our hopes so we 
continued our studies of catalysts for chiral reduction of acetylfluorene. Among 
ruthenium catalysts, those containing the combination of an 6-arene and a chiral 
sulfonated diphenylethanediamine ligand (TsDPEN), first introduced by Noyori  and 
co-workers have been widely applied to synthetic applications in recent years.6,7 In 
2005, Wills and co-workers introduced the tethered ruthenium catalyst, (R,R)-teth-
TsDpen-RuCl 5 (Fig. 1a), reporting that the introduction of the tether greatly 
increases the reaction rate and improves the stability of the catalyst.8 Recent 
research on this and other classes of tethered catalysts has accelerated in recent years 
with several new catalysts and applications reported.9 Moreover such catalysts are 
compatible with the use of formic acid/triethylamine mixtures as hydrogen source 
and solvent, which renders them capable of asymmetric reductions of a wide range 
of substrates under convenient conditions. 
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Scheme 1. Reagents and conditions: a) EtOAc/t-BuOK, Et2O, reflux, 5 h, 48%;  b) 0.3 
mol% (R,R)-teth-TsDpen-RuCl 5, 2:5 HCO2H,Et3N (FA/TEA), 45 min, 91%, 83% ee, 
72%, > 97% ee after recrystallisation;  c) triphosgene, TEA, CH2Cl2, 25°C, 2 h, 90%. 
 
We investigated the reduction of ketone 2 to alcohol 3 using (R,R)-teth-TsDpen-
RuCl 5 in a 5:2 mixture of formic acid/triethylamine and were pleased to obtain the 
alcohol in 64% yield after column chromatography, but were surprised to identify 
the (S)-(-) enantiomer as the major product in 76% ee. Based on the report of Zhou 
and co-workers10 we changed the ratio to a 2:5 mixture of formic acid/triethylamine. 
Under these conditions, the yield was improved to 91% and the (S)-(-) enantiomer 
was obtained in 83% ee.  Recrystalization yielded (S)-(-)-1-(9-fluorenyl)ethanol (3) 
in 72% yield and > 97% ee  (Scheme 1). The absolute stereochemistry was verified 
by comparison to the commercially sourced (S)‐isomer and previously prepared (R)-
isomer (further details are given in the Supporting Information) In this synthesis of 
(S)-3, just 45 mg of catalyst was required to generate 3.80 g of product in >97% ee. 
The observed stereochemical outcome, i.e. formation of the S-configuration 
product, was somewhat surprising due to the anticipated R-alcohol outcome for 
reduction of acetophenone derivatives (Fig. 1b),8,9,11 but this can be attributed to the 
additional steric hindrance that the fluorenyl group lends to the ketone forcing the 
larger group into the less sterically-congested region of the catalyst (Fig. 1c) in 
analogy with what has been observed with dialkyl ketones.12  
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Figure 1. a) Catalyst (R,R)-5. B) Approach of acetophenone to (R,R)-5. c) Proposed 
approach of ketone 2 to (R,R)-5.  
 
As well as the success of the reaction, another virtue was the operational simplicity 
with no special preparation of the solvents required other than degassing by a stream 
of nitrogen, which allows direct addition to the ketone which is not stable for 
extended periods. The corresponding chloroformate reagent (4) was then obtained 
by treatment of the alcohol with triphosgene, as previously described.4  
 
 
While we previously investigated the use of FLEC to derivatise a series of racemic 
amino acids, we turned our attention now to the derivatisation of 
tetrahydroquinaldines. These heterocycles have been identified as lead compounds 
in fragment based drug design of bromodomain inhibitors and elaborated in the 
Bromodomain and Extra-Terminal Domain (BET) inhibitor, I-BET-726 which 
contains the S-tetrahydroquinaldine scaffold.13,14 Again we had in mind the utility 
of FLEC not just as an analytical reagent, but as a combined resolving and protecting 
group.  
5 
 
 
 
 
Scheme 2. Reagents and conditions: a) (S)-4, TEA, CH2Cl2, RT, overnight 81% 
mixture, isolated (S,S)-7 11%, (S,R)-7 21%. b) column chromatography, RP-HPLC. c) 
piperidine, DBU, MeOH, 85% (S)-6, 81% (R)-6. d) CH2Cl2, Ac2O, RT, 16h, 90% (S)-
8, 93% (R)-8.  
 
Treatment of tetrahydroquinaldine 6 with FLEC under basic conditions led to 
complete conversion to the carbamate 7 (Scheme 2). The diastereomers were 
isolated from the crude reaction by normal phase silica chromatography and were 
resolved by semi-preparative RP-HPLC (see Supporting Information) to give the 
desired (S,S)-7 and (S,R)-7 in 99% and 94% de respectively. The resultant product 
(S,S)-7 was deprotected to give the (S)-6 enantiomer, as confirmed by independent 
synthesis using phthaloyl-L-leucine as the resolving agent.15 Acetylation yielded the 
BET inhibitor scaffold (S)-8 (Scheme 2), which was shown to be >97% ee by chiral 
chromatography. The absolute stereochemistry was verified by comparison to the 
(S)‐isomers and (R)-isomers prepared by resolution with phthaloyl-leucine (further 
details are given in the Supporting Information),  confirming the successful FLEC-
based diastereomeric resolution.  
. 
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Scheme 3. Reagents and conditions: a) NaCNBH3, AcOH, RT, 5 h, 62%;  b) (S)-4, 
CH2Cl2, RT, overnight, 20%. 
 
As an analytical reagent, we could evaluate the different enantiomers of 10 formed 
either by the aromatic bromination of 6 or by the reduction of 6-bromoquinaldine 9 
(Scheme 3). FLEC derivatisation yielded the diastereomers of 11 which were 
resolved by RP-HPLC (Supporting Information). This provides a means of 
analysing the outcome of attempts at asymmetric quinoline reductions which are 
also desirable transformations (for example, using 5 or other chiral catalysts16).  
 
 
Scheme 4. Reagents and conditions: a) KNO3/H2SO4 in CH2Cl2, RT, 2.5 h, 79% (64% 
12 and 15% 13), b) pyrrolidine, CH2Cl2, 10 min, 60%. 
 
Finally, we examined the potential for the FLEC-group to add regioselection to its 
list of valuable properties, by attempting nitration of Feoc-protected 
tetrahydroquinaldine (Scheme 4). This was inspired by recent comparable 
descriptions of regioselective nitration of Fmoc-protected tetrahydroquinoline and 
phthaloyl-leucinyltetrahydroquinaldine, where the appended group potentially 
hinders access to the C8 position allowing regioselective C6 nitration.17,18 The 
reaction was attempted on the mixture of diastereomers (7), in order to observe any 
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difference that may be due to the diastereomeric form. While the reaction was 
successful and notably no nitration of the Feoc-group was seen, we did observe 
nitration at both C6 (12) and C8 (13) in a 4:1 ratio (further details of the HPLC 
resolution are given in the Supporting Information). Moreover, the ratio of 
regioisomers was the same irrespective of the diastereomeric form. The regioisomer, 
12 was readily isolated by column chromatography and then successfully 
deprotected, to yield the racemic nitroquinaldine 14. While not providing 
regiospecificity, the combination of regioselection, diastereomeric resolution and 
ease of deprotection supports this approach for the elaboration of other chiral amine 
substrates. 
 
 
Conclusion. 
In summary, we have developed a practical synthesis of the chiral derivatising reagent, 
(S)-fluorenylethylchloroformate (FLEC) 4, and shown the utility of the reagent in the 
separation of enantiomers of unusual amines such as tetrahydroquinaldine derivatives. 
The FLEC enantiomers could be utilized as a combined resolving and protecting group 
with potential also for regioselection in synthetic medicinal chemistry applications. 
 
Experimental Section. 
General methods and instrumentation. 
Fluorene and (S)-fluorenylalcohol were supplied by Fluka. Quinaldine was supplied by 
Tokyo Chemical Industry Co. Ltd. (TCI), Japan. (R,R)-teth-TsDpen-RuCl 5 was 
supplied by Johnson Matthey, UK. 6-Bromoquinaldine was supplied by Sigma-Aldrich. 
DIPEA, piperidine, triethylamine, EDC, DMAP and pyridine were purchased from 
Sigma-Aldrich. All other materials were reagent grade and purchased from either 
Sigma-Aldrich, Alfa-Aesar, Merck, Boron Molecular, GL Biochem, Matrix Scientific, 
Indofine Chemicals, Fluorochem or Apollo Scientific. All anhydrous solvents used 
were obtained from an MB SPS-800 Solvent Purification System. 1-(9H-Fluoren-9-
yl)ethan-1-one 2 was prepared following a published procedure.5,19 
The 1H and 13C NMR spectra were acquired on a Bruker Advance III Nanobay 400 
MHz spectrometer coupled to the BACS 60 automatic sample changer and obtained at 
400.13 MHz and 100.62 MHz respectively, with experiments conducted at 298 K. All 
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spectra were processed using MestReNova 6.0 software. Chemical shifts (δ) for all the 
1H NMR spectra were reported in parts per million (ppm) referenced to an internal 
standard of residual proteo-solvent: δ 2.50 ppm for d6-dimethylsulfoxide (d6-DMSO), 
δ 3.31 ppm d4–methanol (d4-CD3OD), and δ 7.26 ppm for d1-chloroform (CDCl3). The 
1H NMR spectra were reported as follows: chemical shift (δ), multiplicity, coupling 
constant (J) in Hertz (Hz), peak integration and assignment. In reporting the spectral 
data, the following abbreviations have been used: Ar = aromatic, s = singlet, d = 
doublet, t = triplet, q = quartet, sext = sextet, hept = heptet, m = multiplet, br = broad. 
Chemical shifts (δ) for all the 13C NMR were also reported in parts per million (ppm) 
referenced to an internal standard of residual proteo-solvent: δ 39.52 ppm for d6-
dimethylsulfoxide (d6-DMSO), δ 49.00 ppm for d4-methanol (CD3OD), δ 77.16 ppm 
for d1-chloroform (CDCl3). The 
13C NMR spectra were reported as chemical shifts: (δ) 
and signals assigned as: (CO) = carbonyl carbon, (C) = quaternary carbon, (CH) = 
methine carbon, (CH2) = methylene carbon and (CH3) = methyl carbon. 
Analytical Thin Layer Chromatography (TLC) was performed on silica gel 60 F254 pre-
coated plates (0.25 mm, Merck ART 5554) and visualised by ultraviolet light, iodine 
or phosphomolybdic acid stain as was necessary. silica gel P60 (Velocity Scientific 
Solution) was used for silica gel flash chromatography. 
Analytical Reverse-Phase High Performance Liquid Chromatography (RP-HPLC) was 
conducted on an Agilent Infinity 1260 system fitted with Zorbax Eclipse Plus C-8 
Rapid Resolution 4.6 × 100 mm, 3.5 μm column (Agilent Technologies, Palo Alto, 
CA) using a binary solvent system (solvent A: 0.1% TFA, 99.9% H2O; solvent B: 0.1% 
TFA, 99.9% acetonitrile (ACN), with ultraviolet (UV) detection at 254 nm. Except 
where otherwise indicated, the method used a linear gradient elution profile of 5-80% 
solvent B over 10 min at a flow rate of 1 mL/min.  
Preparative RP-HPLC was conducted on Agilent Infinity 1260 system fitted with 
Alltima C-8, 22 × 250 mm, 5 μm column.  This system used 0.1% TFA in Milli-Q 
water as the aqueous buffer and 0.1% TFA in ACN as the organic buffer. The eluting 
profile was a linear gradient of 0 - 80% ACN in water over 40 min at 10 - 20 mL/min.  
Analytical and semi-preparative chiral-HPLC were conducted on an Agilent Infinity 
1260 system fitted with either of Lux 5µ Cellulose-1 or Amylose-2 columns 150 × 4.60 
mm, as indicated. Isocratic elution of 10% ethanol and 90% petroleum spirits at a flow 
rate of 1 mL/min was used with UV detection at 254 nm.  
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All high resolution mass spectrometry (HRMS) analyses were performed on an Agilent 
6224 time-of-flight (TOF) Mass spectrometer coupled to an Agilent 1290 Infinity liquid 
chromatography (LC/MS) (Agilent, Palo Alto, CA). All data were acquired and 
reference mass corrected via a dual‐spray electrospray ionisation (ESI) source. Each 
scan or data point on the Total Ion Chromatogram (TIC) is an average of 13,700 
transients, producing one spectrum every second. Mass spectra were created by 
averaging the scans across each peak and background subtracting against the first 10 
seconds of the TIC. The acquisition was performed using the Agilent Mass Hunter Data 
Acquisition software version B.05.00 Build 5.0.5042.2 and analysis were performed 
using Mass Hunter Qualitative Analysis version B.05.00 Build 5.0.519.13. MS 
conditions were: Drying gas flow: 11 L/min; Nebuliser: 45 psi; Drying gas 
temperature: 325 °C; Capillary voltage (Vcap): 4000 V; Fragmentor: 160 V; Skimmer: 
65 V; OCT RFV: 750 V; Scan range acquired: 100–1500 m/z; Internal reference ions: 
Positive Ion Mode  m/z = 121.050873 and 922.009798. Chromatographic separation 
was performed using an Agilent Zorbax SB-C18 Rapid Resolution HT 2.1 × 50 mm, 
1.8 μm column (Agilent Technologies, Palo Alto, CA) using an acetonitrile gradient 
(5% to 100%) over 3.5 min at 0.5 mL/min. Solvent A = aqueous 0.1% formic acid, 
Solvent B = ACN /0.1% formic acid. 
All low resolution mass spectrometry (LRMS) analyses were performed on an Agilent 
ultra-HPLC/MS (1260/6120) mass spectrometer coupled to an Agilent 1290 Infinity 
system. LC/MSD Chemstation Rev.B.04.03 coupled with Masshunter Easy Access 
Software was used. MS conditions are: Drying gas temperature: 325°C; Capillary 
voltage (Vcap): 3000 V; Scan range acquired: 100–1000 m/z; Ion mode: API-ES; 
Chromatographic separation was performed using an Agilent Poroshell 120 EC-C18 3 
× 50 mm, 2.7 μm. Solvent A = aqueous 0.1% formic acid, Solvent B = ACN /0.1% 
formic acid. A gradient mixture of B (5% to 100%) was used over 2.5 min at 0.5 
mL/min. Melting points were determined on a Mettler Toledo MP50 melting point 
system and are presented uncorrected.  
 
(S)-1-(9H-Fluoren-9-yl)ethan-1-ol  (S)-3.5  
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A 5:2 (molar) azeotrope of formic acid and TEA (30 mL) and (R,R)-teth-TsDpen-RuCl 
5 (45 mg, 0.080 mmol, 0.3% molar ratio) was degassed under N2 for 30 min. To the 
degassed mixture was added ketone 2 (5.25 g, 25.2 mmol) and the reaction mixture was 
stirred at 40°C for 14 h. The reaction mixture was cooled to RT and poured into water 
(150 mL) then acidified with 1 M aqueous HCl to pH ~ 3. The aqueous layer was 
extracted with diethyl ether (3 × 100 mL) and the combined organic layers were dried 
(Na2SO4), filtered, and concentrated in vacuo to give the crude product (4.80g, 91%, 
83% ee) The residue was purified by column chromatography (2 - 60% EtOAc in 
petroleum benzine) then recrystallised (3% EtOAc in petroleum benzene) to provide 
the title compound (S)-3 as white needles (3.80 g, 72%, > 97% ee). Mp: 101 – 102°C 
(lit.5 mp: 100 – 102 °C). TLC: Rf (15% EtOAc in petroleum benzine) = 0.2. Analytical 
RP-HPLC: tR = 2.62 min, purity >99%. ESI-HRMS (m/z): calcd for C15H15O
+ [M+H]+, 
211.1045; found, 211.1043. Analytical CHPLC (Lux Cellulose-1): tR = 5.63 min (S) 
and 6.44 min (R), > 97% (ee). 1H NMR (400 MHz, CDCl3) δ 7.79 (d, J = 7.5 Hz, 2H, 
ArH), 7.76 – 7.72 (m, 1H, ArH), 7.58 – 7.54 (m, 1H, ArH), 7.45 – 7.38 (m, 2H, ArH), 
7.37 – 7.30 (m, 2H, ArH), 4.59 (qd, J = 6.3, 4.4 Hz, 1H, CH(OH)), 4.19 (d, J = 4.4 Hz, 
1H, CHCH(OH), 1.65 (s, 1H, OH) and 0.96 (d, J = 6.3 Hz, 3H, CH3) ppm. 
13C NMR 
(101 MHz, CDCl3) δ 144.0 (C), 143.9 (C), 142.0 (C), 141.8 (C), 127.5 (2 × CH), 127.0 
(CH), 126.9 (CH), 125.7 (CH), 124.8 (CH), 120.0 (CH), 119.9 (CH), 70.5 (CH), 54.6 
(CH) and 18.7 (CH3) ppm.  
 
(S)-1-(9H-Fluoren-9-yl)ethyl carbonochloridate [(S)-FLEC] (S)-4.1,4,5,19  
 
To a stirred solution of triphosgene (128 mg, 0.431 mmol) in dry CH2Cl2 (4 mL) at 0°C 
was added (S)-3 (208 mg, 0.991 mmol) in one portion followed by a solution of pyridine 
(110 mg, 1.39 mmol) in CH2Cl2 (5 mL) over 30 minutes at 0 – 5 °C. The mixture was 
allowed to warm slowly to RT and stirring was continued for a further 2.5 h. The 
resulting mixture was washed with ice-cold water (3 × 25 mL), dried (Na2SO4) and 
concentrated in vacuo to give the title compound (S)-1-(9H-fluoren-9-yl)ethyl 
carbonochloridate (4) as a clear oil (243 mg, 90%). The 1H NMR of the isolated product 
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showed 95% purity, with the remaining 5% being identified as the starting alcohol. 1H 
NMR (400 MHz, CDCl3) δ 7.76 (dd, J = 7.5, 3.9 Hz, 2H, ArH), 7.68 (dd, J = 7.5, 0.9 
Hz, 1H, ArH), 7.53 – 7.50 (m, 1H, ArH), 7.46 – 7.39 (m, 2H, ArH), 7.38 – 7.30 (m, 
2H, ArH), 5.67  (qd, J = 6.4, 4.4 Hz, 1H, CHCH3), 4.40 (d, J = 4.4 Hz, 1H, CHCHCH3), 
0.83 (d, J = 6.4 Hz, 3H, CH3) ppm. 
13C NMR (101 MHz, CDCl3) δ 150.4 (CO), 142.2 
(C), 142.1 (C), 141.9 (C), 141.7 (C), 128.23 (CH), 128.17 (CH), 127.50 (CH), 127.45 
(CH), 126.3 (CH), 124.5 (CH), 120.3 (CH), 120.2 (CH), 81.9 (CH), 51.1 (CH) and 13.9 
(CH3) ppm. 
 
 (S,S) and (S,R)-1-(9H-Fluoren-9-yl)ethyl-2-methyl-3,4-dihydroquinoline-1(2H)-
carboxylate 7.  
 
To a solution of racemic tetrahydroquinaldine (THQ) (6) (352 mg, 2.4 mmol) in CH2Cl2 
(12 mL) at 0°C was added (S)-4 (980 mg, 3.6 mmol) and TEA (290 mg, 2.80 mmol). 
The mixture was stirred overnight at RT, the solvent was evaporated in vacuo and the 
residue was taken up in EtOAc and washed with 1 M aqueous HCl (3 × 40 mL) and 
brine (1 × 40 mL). The organic layer was dried (Na2SO4), concentrated in vacuo and 
the residue was purified by silica gel column chromatography (3 - 60% EtOAc in 
petroleum benzine) to afford 7 (750 mg, 81%, <1% de) as a white solid. The 
diastereomers were resolved by RP-HPLC (35 - 80% ACN in 0.1% aq. TFA) to give 
(S,S)-7 (80 mg, 11%, 99% de) and (S,R)-7 (150 mg, 21%, 94% de). 
(S,S)-7:  Mp 57 – 59 °C. TLC: Rf  (10% EtOAc in petroleum benzine) = 0.34. Analytical 
RP-HPLC: 20-80% solvent B, 5 minutes, tR = 3.83 min (S/S), purity >99% (de). ESI-
HRMS (m/z): calcd for C26H26NO2
+ [M+H]+, 384.1958; found, 384.1966. 1H NMR (400 
MHz, CDCl3) δ 7.76 (d, J = 7.6 Hz, 2H, ArH), 7.59 (t, J = 8.7 Hz, 2H, ArH), 7.50 (d, J 
= 7.5 Hz, 1H, ArH), 7.43 – 7.29 (m, 3H, ArH), 7.26 – 7.02 (m, 4H, ArH), 5.81 – 5.66 
(m, 1H, CHCHCO), 4.72 – 4.54 (m, 1H, NCH), 4.38 (d, J = 3.1 Hz, 1H, CHCHCO), 
2.78 – 2.59 (m, 2H, CCH2), 2.27 (td, J = 12.9, 6.6 Hz, 1H, CCH2CH2), 1.55 (td, J = 
13.3, 6.9 Hz, 1H, CCH2CH2), 1.20 (d, J = 6.5 Hz, 3H, OCHCH3) and 0.83 (d, J = 6.3 
Hz, 3H, NCHCH3) ppm. 
13C NMR (101 MHz, CDCl3) δ 154.7 (CO), 143.6 (C), 143.5 
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(C), 142.2(C), 141.7 (C), 136.7 (C), 132.3 (C), 127.8 (CH), 127.7 (CH), 127.6 (CH), 
127.2 (CH), 127.0 (CH), 126.3 (CH), 126.0 (CH), 125.7 (CH), 124.8 (CH), 124.3 (CH), 
120.0 (CH), 119.9 (CH), 74.3 (CH), 52.2 (CH), 49.9 (CH), 31.5 (CH2), 25.5 (CH2), 19.8 
(CH3) and 14.9 (CH3) ppm. 
(S,R)-7: Mp: 103 – 105°C. TLC: Rf (10% EtOAc in petroleum benzine) = 0.28. . 
Analytical RP-HPLC: 20-80% solvent B, 5 minutes, tR = 3.95 min (S/R) >99% purity, 
94% (de). ESI-HRMS (m/z):  calcd for C26H26NO2
+ [M+H]+, 384.1958; found, 
384.1965. 1H NMR (400 MHz, CDCl3) δ 7.72 (dd, J = 7.5, 2.9 Hz, 2H, ArH), 7.53 (dd, 
J = 12.4, 7.8 Hz, 2H, ArH), 7.41 – 7.27 (m, 3H, ArH), 7.25 – 7.06 (m, 5H, ArH), 5.80 
– 5.71 (m, 1H, CHCHCO), 4.77 – 4.65 (m, 1H, NCH), 4.29 (d, J = 3.8 Hz, 1H, 
CHCHCO), 2.79 – 2.64 (m, 2H, CCH2), 2.36 – 2.24 (m, 1H, CCH2CH2), 1.56 (td, J = 
13.4, 6.8, Hz, 1H, CCH2CH2), 1.24 (d, J = 6.5 Hz, 3H, OCHCH3) and 0.78 (d, J = 6.4 
Hz, 3H, NCHCH3) ppm. 
13C NMR (101 MHz, CDCl3) δ 154.6 (CO), 143.5 (C), 143.4 
(C), 142.2 (C), 141.7 (C), 136.7 (C), 132.7 (C), 127.8 (CH), 127.7 (CH), 127.5 (CH), 
127.2 (CH), 126.9 (CH), 126.4 (CH), 126.19 (CH), 126.17 (CH), 124.7 (CH), 124.4 
(CH), 120.0 (CH), 119.8 (CH), 74.0 (CH), 51.9 (CH), 49.9 (CH), 31.5 (CH2), 25.5 
(CH2), 19.8 (CH3) and 14.9 (CH3) ppm. 
 
 
 (S)-2-Methyl-1,2,3,4-tetrahydroquinoline, (S)-6. 15  
 
To a solution of carbamate (S,S)-7 (40 mg, 0.10 mmol) in MeOH (1.0 M) was added 
piperidine (0.05 mL) and DBU (0.05 mL). The mixture was stirred at RT for 2 h. The 
solvent was removed in vacuo and the residue was purified by column chromatography 
(0 - 15% EtOAc in petroleum benzine) to give the title compound (S)-6 as a pale yellow 
oil (13 mg, 85%). TLC: Rf (10% EtOAc in petroleum benzine) = 0.80. Analytical RP-
HPLC: tR = 3.80 min, >99% purity. ESI-HRMS (m/z):  calcd for C10H14N
+  [M+H]+, 
148.1121; found, 148.1122. 1H NMR (400 MHz, CDCl3) δ 6.99 – 6.92 (m, 2H, ArH), 
6.63 – 6.58 (m, 1H, ArH), 6.50 – 6.44 (m, 1H, ArH), 3.88 – 3.48 (br, 1H, NH), 3.49 – 
3.29 (m, 1H, CH), 2.91 – 2.65 (m, 2H, CH2), 2.00 – 1.85 (m, 1H, CH2), 1.65 – 1.59 (m, 
1H, CH2) and 1.23 – 1.18 (d, J = 6.3 Hz, 3H, CH3) ppm. 13C NMR (101 MHz, CDCl3) 
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δ 144.9 (C), 129.4 (CH), 126.8 (CH), 121.2 (C), 117.1 (CH), 114.1 (CH), 47.3 (CH), 
30.3 (CH2), 26.7 (CH2) and 22.8 (CH3) ppm. 
 
(R)-2-Methyl-1,2,3,4-tetrahydroquinoline  (R)-6.21 
 
To a solution of carbamate (S,R)-7  (40 mg, 0.10 mmol) in MeOH (1.0 M) was treated 
as for  (S,S)-7a above to give (R)-6 as an oil (12 mg, 81%). TLC: Rf (10% EtOAc in 
petroleum benzine) = 0.8. Analytical RP-HPLC: tR = 3.81 min, purity >99%.  The data 
matched that previously reported for (S)-6 above.  
 
 (S)-1-(2-Methyl-3,4-dihydroquinolin-1(2H)-yl)ethan-1-one (S)-8.  
 
To a solution of (S)-1-(2-Methyl-3,4-dihydroquinolin-1(2H)-yl)ethan-1-one (S)-6 (30 
mg, 0.20 mmol) (1.0 equiv.) in dichloromethane (CH2Cl2) (0.1 M) at 0°C was added 
acetic anhydride (4.0 equiv.) and the mixture was allowed to stir at room temperature 
(RT) for 16 h. The mixture was poured into ice-water and acidified with 1 M aqueous 
HCl to pH~ 4. The aqueous layer was extracted with CH2Cl2 (3 × 100 mL). The 
combined organic layers were dried (Na2SO4), and concentrated in vacuo to give (S)-8 
(35 mg, 90%) as a colourless crystalline solid. Mp: 50 – 51°C. TLC: Rf (15% EtOAc in 
petroleum benzine) = 0.3. Analytical RP-HPLC: 6.62 min, >99% purity. ESI-HRMS 
(m/z): calcd for C12H16NO
+ [M+H]+, 190.1226; found, 190.1227. Analytical CHPLC: 
Lux Amylose-2, tR = 5.07 min (S) 97% (ee). 
1H NMR (400 MHz, CDCl3) δ 7.24 – 7.03 
(m, 4H, ArH), 4.78 (br.s, 1H, CHCH3), 2.67 – 2.44 (m, 2H, CCH2), 2.41 – 2.28 (m, 1H, 
CH3CHCH2), 2.14 (s, 3H, C(O)CH3), 1.41 – 1.23 (m, 1H, CH3CHCH2) and 1.12 (d, J 
= 6.5 Hz, 3H, CH3) ppm. 
13C NMR (101 MHz, CDCl3) δ 169.7 (CO), 166.3 (C), 137.7 
(C), 127.4 (CH), 126.2 (CH), 125.9 (CH), 125.6 (CH), 48.4 (CH), 32.7 (CH2), 26.2 
(CH2), 23.0 (CH3) and 20.3 (CH3) ppm. The product was identical to a sample obtained 
by acetylation of (S)-6 from diastereomeric resolution.15 
 
(R)-1-(2-Methyl-3,4-dihydroquinolin-1(2H)-yl)ethan-1-one (R)-8. 
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(R)-1-(2-Methyl-3,4-dihydroquinolin-1(2H)-yl)ethan-1-one (2R)-6 (25 mg, 0.18 
mmol) was treated as for (2S)-6 above to give the desired compound (R)-1-(2-methyl-
3,4-dihydroquinolin-1(2H)-yl)ethan-1-one (R)-8 (30 mg, 93%) as a clear oil. TLC: Rf 
(15% EtOAc in petroleum benzine) = 0.3. Analytical RP-HPLC tR = 6.62 min, >99% 
purity. ESI-HRMS (m/z): calcd for C12H16NO
+ [M+H]+, 190.1226; found, 190.1227. 
Analytical CHPLC (Lux Amylose-2: tR = 6.08 min (R) 94% (ee). The data matched that 
previously reported for (S)-8 above.  
 
6-Bromo-2-methyl-1,2,3,4-tetrahydroquinoline 10.16b,20  
 
To a solution of 6-bromo-2-methylquinoline (6-bromoquinaldine, 9) (2.00 g, 9.01 
mmol) in glacial AcOH (5.0 mL) kept below 30°C was added NaCNBH4 (1.13 g, 18.1 
mmol) portionwise. The mixture was stirred at RT for 5 h. The reaction mixture was 
then neutralised by saturated aqueous NaHCO3 and extracted with Et2O (3 × 50 mL). 
The combined organic layers were washed with brine (20 mL), dried (Na2SO4), and 
concentrated in vacuo. The residue was purified by column chromatography to provide 
the title compound 10 as a brown solid (1.26 g, 62%). Mp: 43-45°C. TLC: Rf (10% 
EtOAc in petroleum benzine) = 0.5. ESI-HRMS (m/z): calcd for C10H13BrN
+ 
[M(79Br)+H] +, 227.0258; found, 227.0252. Analytical CHPLC: tR = 3.25 min and 3.75 
min (racemic). 1H NMR (400 MHz, CDCl3) δ 7.07  (d, J = 2.1 Hz, 1H, ArH), 7.04  (d, 
J = 8.4 Hz, 1H, ArH),  6.35 (d, J = 8.4 Hz, 1H, ArH), 3.59 (br.s, 1H, NH), 3.45 – 3.29 
(m, 1H, NHCH), 2.89 – 2.56 (m, 2H, CH2), 2.02 – 1.82 (m, 1H, CH2), 1.62 – 1.44 (m, 
1H, CH2) and 1.21 (d, J = 6.3 Hz, 3H, CH3) ppm. 
13C NMR (101 MHz, CDCl3) δ 
133.3(CH), 132.9 (C), 131.0 (CH), 129.0 (C), 125.9 (CH), 123.3 (C), 51.8 (CH), 26.6 
(CH2), 24.5 (CH2) and 18.0 (CH3) ppm. 
 
(S,S)- and (S,R)-1-(9H-Fluoren-9-yl)ethyl-2-methyl-3,4-dihydroquinoline-1(2H)-
carboxylate 11. 
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Compound 11 was prepared as for 7, above using 10 (24mg, 0.15mmol) and (S)-4 (42 
mg, 0.16 mmol). The products were purified by column chromatography (10% Et2O in 
petroleum benzine) to yield a mixture of diastereoisomers 11 as a colourless oil (10 mg, 
20%).  
 
Rf (10% Et2O in petroleum benzine) = 0.3. Analytical RP-HPLC: 80-100% B, 9 
minutes, tR = 3.38, 3.55 min (S/R) >99% purity. ESI-HRMS (m/z): calcd for 
C26H25NO2
81Br+ [M+H]+, 464.1048; found, 464.1053. 1H NMR (400 MHz, CDCl3) δ 
7.78 (d, J = 7.5 Hz, 2H, ArH) 7.72 (dd, J = 7.5, 2.9 Hz, 2H, ArH), 7.59 (dd, J = 7.8, 1 
Hz, 1H, ArH) 7.54 (d, J = 7.8 Hz, 1H, ArH), 7.50 (d, J = 7.8 Hz, 1H, ArH) 7.42 – 7.17 
(m, 15H, ArH), 5.76 – 5.71 (m, 2H, CHCHCO), 4.67  (q, 1H, NCH), 4.61  (q, 1H, 
NCH), 4.36 (d, J = 3.8 Hz, 1H, CHCHCO) 4.29 (d, J = 3.8 Hz, 1H, CHCHCO), 2.73 – 
2.58 (m, 4H, CCH2), 2.27 – 2.17 (m, 2H, CCH2CH2), 1.56 (m, 5H, CCH2CH2), 1.19 (d, 
J = 6.5 Hz, 3H, OCHCH3)  1.15 (d, J = 6.5 Hz, 3H, OCHCH3) and 0.89  (d, J = 6.4 Hz, 
3H, NCHCH3) 0.8  (d, J = 6.4 Hz, 3H, NCHCH3) ppm. 
 
(S)-1-(9H-Fluoren-9-yl)ethyl-2-methyl-6-nitro-3,4-dihydroquinoline-1(2H)-
carboxylate 12. 
 
To a solution of 7 (58 mg, 0.15 mmol) in CH2Cl2 (2.0 mL) at RT was added 
concentrated sulphuric acid (15 mg, 0.15 mmol) and potassium nitrate (15 mg, 0.15 
mmol). The mixture was stirred for 2.5 h The mixture was poured over ice and then 
extracted with CH2Cl2 (3 × 20 mL) and washed successively with 5% aqueous NaHCO3 
(20 mL), water (20 mL) and brine (20 mL). The solution was dried (Na2SO4) and 
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concentrated in vacuo. The residue was purified by column chromatography (15% 
EtOAc in petroleum spirit) to afford 12 (diastereomeric mixture of (S,S) and (S,R)) (41 
mg, 64%). 
12: TLC: Rf (15% EtOAc in petrol) = 0.4. ESI-HRMS (m/z): calcd for C26H24N2O4
+ 
[M]+, 428.1736; found, 428.1736. Analytical RP-HPLC: 20-100% CH3CN in 0.05% 
TFA at a flow rate of 0.2 mL/min over 10 min on a C8, 100 Å, 5 μm, (150 × 4.6 mm 
I.D.) column (Phenomenex), tR = 15.01 min and 15.12 min (equal diastereomeric 
mixture of (S,S) and (S,R)), purity >99%.  1H NMR (400 MHz, CDCl3) δ 7.97 – 7.87 
(m, 2H, ArH), 7.70 (s, 1H), 7.59 (dd, J = 4.7, 4.1 Hz, 2H, ArH), 7.52 – 7.47 (m, 1H, 
ArH), 7.35 – 7.26 (m, 4H, ArH), 7.13 – 7.01 (m, 1H, ArH), 5.68 (qd, J = 6.5, 3.7 Hz, 
1H, COCH), 4.65 – 4.55 (m, 1H, NCH), 4.24 (d, J = 3.3 Hz, 1H, COCHCH), 2.75 (ddd, 
J = 13.4, 9.2, 5.1 Hz, 2H, CH2), 2.14 – 2.00 (m, 1H, CH2), 1.60 – 1.53 (m, 1H, CH2), 
1.12 – 1.08 (m, 3H, CH3) and 0.94 (d, J = 6.4 Hz, 3H, NCHCH3) ppm. 
Further elution yielded the 8-nitro substituted regioisomer 13 as mixture of (S,S) and 
(S,R) diastereomers. Analytical RP-HPLC: tR = 15.25 min and 15.35 min (equal 
diastereomeric mixture of (S,S) and (S,R)), purity 70%. (10 mg, 15%): TLC: Rf (40% 
EtOAc in petrol) = 0.30. ESI-LRMS (m/z): C26H25N2O4
+ [M+H]+, 429.18. 1H NMR 
(400 MHz, CDCl3) δ 8.15 – 7.95 (m, 2H, ArH), 7.65 – 7.59 (m, 3H, ArH), 7.52 – 7.47 
(m, 1H, ArH), 7.35 – 7.26 (m, 4H, ArH), 7.13 – 7.01 (m, 1H, ArH), 5.81 – 5.75 (m 1H, 
COCH), 4.65 – 4.55 (m, 1H, NCH), 1.39 – 1.25 (m, 1H, COCHCH), 2.85 – 2.74 (m, 
2H, CH2), 2.20 – 2.11 (m, 1H, CH2), 1.75 – 1.60 (m, 1H, CH2), 1.21 – 1.19 (m, 3H, 
CH3) and 0.80 (d, J = 6.4 Hz, 3H, NCHCH3) ppm. 
 
2-Methyl-6-nitro-1,2,3,4-tetrahydroquinoline 14.13  
 
To a solution of carbamate, 12 (37 mg, 0.091 mmol) in CH2Cl2 (0.01 M) was added 
pyrrolidine (1.0 mL). The mixture was stirred at RT for 10 - 15 min. The solvent was 
removed in vacuo to give the crude product as a yellow liquid. The crude liquid was 
purified by RP-HPLC (60 - 100% ACN in water and 0.1% TFA) to give 14 as a yellow 
solid (10 mg, 60%).  
Mp: 132.0 - 133.4 °C (lit.13 mp: 140 – 142 °C). TLC: Rf (15% EtOAc in petroleum 
benzine) = 0.4. Analytical RP-HPLC: tR = 3.20 min, purity >99%. ESI-HRMS (m/z): 
17 
 
calcd for C10H13N2O2
+ [M+H]+, 193.0972; found, 193.0970. 1H NMR (400 MHz, 
CDCl3) δ 7.93 – 7.84 (m, 2H, ArH), 6.39 – 6.33 (m, 1H, ArH), 4.55 (br.s, 1H, NH), 
3.59 – 3.49 (m, 1H, CHCH3), 2.83 – 2.78 (m, 2H, CH2 ), 2.04 – 1.96 (m, 1H, CH2), 
1.61 – 1.51 (m, 1H, CH2) and 1.27 (d, J = 6.4 Hz, 3H, CH3) ppm. 13C NMR (101 MHz, 
CDCl3) δ 150.4 (C), 125.9 (CH), 124.4 (CH), 121.2 (C), 119.8 (C), 112.2 (CH), 47.3 
(CH), 28.9 (CH2), 26.3 (CH2) and 22.3 (CH3) ppm.   
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